MyFinsight
Home
Blog
About
Proceeds from maturities
of investments
$141,019K
(-15.04%↓ Y/Y)
Atm offering, net of
fees
$22,573K
Proceeds from exercises
of stock options...
$1,013K
(99.80%↑ Y/Y)
Proceeds from sales of
investments
$38,466K
Net cash provided by
investing activities
$109,431K
(157.45%↑ Y/Y)
Net cash provided by
financing activities
$23,586K
(4552.07%↑ Y/Y)
Canceled cashflow
$70,054K
Net (decrease)
increase in cash, cash...
$7,845K
(293.80%↑ Y/Y)
Canceled cashflow
$125,172K
Purchases of investments
$70,054K
(-43.27%↓ Y/Y)
Stock-based compensation
$11,133K
(-17.82%↓ Y/Y)
Accounts payable
$1,830K
(182.84%↑ Y/Y)
Accrued expenses
$1,341K
(-90.84%↓ Y/Y)
Amortization of right-of-use
assets
$157K
(40.18%↑ Y/Y)
Accrued interest, net of
interest receivable on...
-$120K
(-1190.91%↓ Y/Y)
Interest expense related
to operating lease...
$111K
(1287.50%↑ Y/Y)
Net cash used in
operating activities
-$125,172K
(-165.98%↓ Y/Y)
Canceled cashflow
$14,692K
Net loss
-$128,022K
(-95.27%↓ Y/Y)
Prepaid expenses and
other current assets
$10,736K
(110.96%↑ Y/Y)
Amortization of investment
premiums
$885K
(-62.99%↓ Y/Y)
Lease liability
-$191K
(-46.92%↓ Y/Y)
Realized gain on
investments
$30K
(650.00%↑ Y/Y)
Back
Back
Cash Flow
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
source: myfinsight.com